| Literature DB >> 33228722 |
Shiro Murata1,2, Yuka Machida3, Masayoshi Isezaki3, Naoya Maekawa4, Tomohiro Okagawa4, Satoru Konnai3,4, Kazuhiko Ohashi3,4.
Abstract
BACKGROUND: Marek's disease virus (MDV) causes malignant lymphomas in chickens (Marek's disease, MD). MD is currently controlled by vaccination; however, MDV strains have a tendency to develop increased virulence. Distinct diversity and point mutations are present in the Meq proteins, the oncoproteins of MDV, suggesting that changes in protein function induced by amino acid substitutions might affect MDV virulence. We previously reported that recent MDV isolates in Japan display distinct mutations in Meq proteins from those observed in traditional MDV isolates in Japan, but similar to those in MDV strains isolated from other countries.Entities:
Keywords: Japanese strain; Marek’s disease; Marek’s disease virus; Meq; Whole genome sequencing
Year: 2020 PMID: 33228722 PMCID: PMC7684920 DOI: 10.1186/s12985-020-01456-1
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
MDV strains used for the analyses in this study
| Country | Strain | Virulence | Genome size (bp) | Accession No | References |
|---|---|---|---|---|---|
| Japan | Kgs-c1 | – | 174,999 | LC589272 | This study |
| USA | 648a | vv + | 176,080 | JQ806361 | Spatz et al. [ |
| Md5 | vv | 177,874 | NC_002229 | Tulman et al. [ | |
| Md11 | vv | 170,950 | AY510475 | Niikura et al. [ | |
| RB-1B | vv | 178,246 | EF523390 | Spatz et al. [ | |
| GA | v | 174,077 | AF147806 | Lee et al. [ | |
| CU-2 | m | 176,922 | EU499381 | Spatz et al. [ | |
| China | GX0101 | vv | 178,101 | JX844666 | Su et al. [ |
| LMS | vv | 177,526 | JQ314003 | Cheng et al. [ | |
| 814 | m/vaccine | 172,541 | JF742597 | Zhang et al. [ | |
| CC/1409 | – | 175,561 | KU744560 | Lv et al. [ | |
| HNGS101 | – | 175,888 | MG432697 | He et al. [ | |
| HNLC503 | – | 178,195 | MG518371 | – | |
| HS/1412 | – | 175,532 | KU744561 | Lv et al. [ | |
| J-1 | – | 176,118 | KU744555 | Lv et al. [ | |
| JL/1404 | – | 176,083 | KU744559 | Lv et al. [ | |
| LCC | – | 175,525 | KU744556 | Lv et al. [ | |
| LCY | – | 175,319 | KX290013 | Zhang et al. [ | |
| LTS | – | 176,023 | KU744557 | Lv et al. [ | |
| WC/1203 | – | 176,057 | KU744558 | Lv et al. [ | |
| Poland | Polen5 | hv** | 177,821 | MF431496 | Trimpert et al. [ |
| Israel | EU-1 | hv | 177,828 | MF431494 | Trimpert et al. [ |
| Hungary | ATE2539 | vv+ | 177,868 | MF431493 | Trimpert et al. [ |
| England | pC12:130 | vv | 183,850* | FJ436096 | Spatz et al. [ |
| Hungary | MD70/13 | v | 177,844 | MF431495 | Trimpert et al. [ |
| Netherland | CVI988 | m/vaccine | 178,311 | DQ530348 | Spatz et al. [ |
*The length of pC12:130 genome contains a vector sequence
**Hyper virulent (hv): Recent field strains isolated in Europe with a history of high virulence but not pathotyped within m–vv+ grading scheme [46]
Non-synonymous differences in the amino acid sequences in the coding regions between Kgs-c1 and other MDV strains
| Gene name | Product | Position | JPN | USA | CHN | EU | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kgs-c1 | RB-1B | 648a | Md5 | GA | CU-2 | GX 0101 | LMS | 814 | ATE | C12: 130 | MD70/13 | CVI988 | |||
| MDV004 | 23 kDa nuclear protein | 76 | R | R | R | R | R | R | R | R | |||||
| MDV005 | R-LORF7 (Meq) | 77 | K | K | K | K | K | ||||||||
| 80 | D | D | D | D | D | D | D | D | |||||||
| 115 | V | V | V | V | V | V | V | V | V | ||||||
| 176/235* | P | A | P | P | P | R | R | P | P | P | P | P | |||
| 217/ 276* | P | P | P | P | P | P | P | P | |||||||
| MDV006.6 | B68 (VZV transducing protein) | 14 | T | T | T | T | T | T | T | T | T | T | T | T | |
| MDV010 | v-lipase | 352 | V | V | V | V | V | V | V | V | V | V | V | ||
| MDV015 | UL3 (nuclear phosphoprotein) | 6 | G | G | G | G | G | G | G | G | G | G | P | G | |
| MDV016 | UL4 (nuclear protein) | 244 | V | V | V | V | V | V | V | V | V | V | V | V | |
| MDV018 | UL6 (DNA packaging, minor capsid protein) | 243 | N | N | N | A | N | N | N | N | N | N | N | N | |
| MDV019 | UL7 (DNA packaging/cleavage, capsid protein) | 172 | Q | Q | Q | Q | Q | Q | Q | Q | Q | Q | Q | Q | |
| MDV020 | UL8 (DNAhelicase-primase associated protein) | 84 | E | ||||||||||||
| MDV020.5 | UL8.5 (origin binding protein) | 42 | G | G | G | G | G | G | G | G | G | ||||
| 462 | V | V | V | V | V | V | V | V | V | V | V | V | |||
| MDV021 | UL9 (origin binding protein) | 395 | G | G | G | G | G | G | G | G | G | ||||
| 815 | V | V | V | V | V | V | V | V | V | V | V | V | |||
| MDV040 | UL27 (glycoprotein B) | 537 | S | S | S | S | S | S | S | S | S | S | S | S | |
| MDV042 | UL29 (single-strand DNA binding protein) | 918 | V | V | V | V | |||||||||
| 1,183 | V | V | V | V | |||||||||||
| MDV043 | UL30 (DNA polymerase) | 1,087 | N | N | N | N | N | N | N | N | N | N | N | ||
| 1,095 | V | V | V | V | V | V | V | V | V | V | V | ||||
| MDV044 | UL31 (nuclear phosphoprotein) | 39 | G | G | G | G | G | G | G | G | |||||
| MDV046 | UL32 (DNA packaging) | 415 | I | I | I | I | I | I | I | ||||||
| MDV047 | UL34 (membrane phosphoprotein) | 228 | G | G | G | G | G | G | G | G | G | G | L | G | |
| MDV049** | UL36 (large tegument protein) | 3,241 | K | ||||||||||||
| MDV050 | UL37 (tegument protein) | 3 | V | V | A | V | |||||||||
| 258 | Q | Q | Q | Q | Q | Q | Q | ||||||||
| 521 | R | R | R | R | R | R | R | ||||||||
| MDV051 | UL38 (capsid protein) | 68 | T | T | T | T | T | T | |||||||
| MDV055 | UL42 (DNA polymerase) | 114 | V | V | V | V | V | V | V | ||||||
| 166 | A | A | A | A | A | A | A | A | A | A | A | ||||
| MDV056 | UL43 (probable membrane protein) | 305 | K | K | K | K | T | K | |||||||
| 399 | V | V | V | V | V | V | V | V | V | V | V | ||||
| MDV071 | LORF10 (VZV ORF2) | 34 | W | W | W | W | W | ||||||||
| MDV073 | R-LORF14a (pp38) | 109 | E | E | E | E | |||||||||
| 115 | P | P | P | P | P | P | P | P | P | P | P | P | |||
| MDV084 | ICP4 | 181 | P | P | P | P | P | P | P | P | P | P | P | ||
| 532 | C | C | C | C | C | C | |||||||||
| 1,084 | P | P | P | S | P | ||||||||||
| 1,993 | L | L | L | L | L | L | L | ||||||||
| 2,017 | K | K | K | K | K | K | K | ||||||||
| 2,111 | L | L | L | P | L | L | |||||||||
| MDV091 | US2 (transmission associated protein) | 51 | V | V | V | V | V | V | |||||||
| MDV092 | US3 (serine/threonine protein kinase) | 4 | S | S | S | S | S | S | S | T | |||||
| 109 | S | S | S | S | |||||||||||
| MDV095 | US7 (glycoprotein I) | 3 | L | L | L | L | L | L | Y | L | L | ||||
| 112 | H | H | H | H | H | D | D | H | |||||||
| 142 | A | A | A | A | A | A | A | A | |||||||
| 155 | A | A | A | A | A | A | A | A | |||||||
| 223 | I | I | I | I | I | I | I | I | |||||||
| MDV096 | US8 (glycoprotein E) | 67 | V | V | V | V | V | V | V | V | V | V | V | V | |
| 370 | V | V | V | V | V | V | V | V | V | V | |||||
| 392 | I | I | I | I | I | I | I | I | |||||||
| 455 | D | D | D | D | D | D | T | D | |||||||
| 469 | A | A | A | A | A | A | A | A | |||||||
Italics indicated that the sequences are indentical to those of Kgs-c1
Differences in the coding regions whose functions, including the prediction, were indicated. The differences in the coding regions in Internal Repeat Long (IRL) and Terminal Repeat Short (TRS) between Kgs-c1 and RB-1B were omitted, because the same differences were contained in the same regions in Terminal Repeat Long (TRL) and Internal Repeat Short (IRS), respectively
*The meq genes in CU-2, 814 and CVI988 contain the insertion in the proline-rich repeat (PRR) sequences in the transactivation domain, and therefore, the number of PRRs are increased. The amino acid residues at positions 176 and 235 or 217 and 276 were located at PRR, and those sequences are the same
**Differences in MDV049 (UL36 (large tegument protein)) were indicated except for variable regions at the C-terminus
In-frame deletion and insertion in the coding regions identified in Kgs-c1 and other MDV strains
| Gene name | Product | JPN | USA | CHN | EU | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kgs-c1 | RB-1B | 648a | Md5 | GA | CU-2 | GX 0101 | LMS | 814 | ATE | C12: 130 | MD70/13 | CVI | ||
| MDV013 | UL1 (glycoprotein L) | – | – | – | – | – | – | – | – | – | – | – | – | |
| MDV013.5 | LORF4 (MHC class II beta chain binding protein) | – | – | – | – | – | – | – | – | – | – | – | – | |
| MDV056 | UL43 (probable membrane protein) | – | – | – | – | – | – | – | ||||||
| MDV056 | UL43 (probable membrane protein) | – | – | – | – | – | – | – | ||||||
Italics indicated that the sequences are indentical to those of Kgs-c1
Fig. 1The phylogenetic tree based on sequences from UL to US. The tree of UL–US regions from Kgs-c1 and MDV strains isolated in other countries was generated based on the minimum evolution algorithm with a bootstrap analysis of 1000 replicates. The MDV genomes were classified into two clusters, Eurasia and North America. The scale indicates divergence time
Fig. 2Phylogenetic trees based on alignment of meq genes from Kgs-c1 and MDV strains. The tree was generated using the minimum evolutionary algorithm with a bootstrap analysis of 1000 replicates. The meq genes used in this analysis were mainly classified into three clusters, North America, other regions including Eurasian countries, and L-meq. Numbers indicate bootstrap percentages (1000 replicates). Arrow heads indicate MDV strains used for the phylogenetic analysis described in Fig. 1. The scale indicates divergence time
Fig. 3Phylogenetic trees based on alignment of the UL36 genes from Kgs-c1 and MDV strains. The tree was generated using the minimum evolutionary algorithm with a bootstrap analysis of 1000 replicates. The UL36 genes from MDV strains used in the analysis described in Fig. 1 were compared. The UL36 genes used in this analysis were mainly classified into two clusters, North America and Eurasia. Numbers indicate bootstrap percentages (1000 replicates). The scale indicates divergence time